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Introduction 
Early in the influenza A(H1N1)2009 pandemic, children <5 years were considered to be at 
increased risk of contracting the disease and developing complications (1-2). With the start of 
the mitigation phase, surveillance had to be enhanced to support decision making and sev-
eral surveillance systems were reinforced, adapted or set up. 
The paediatric outpatient population was thought to be insufficiently covered by the Sentinel 
General Practitioners (SGP) network for children <5 years (3) and the consultation behaviour 
of young children’s parents could not be predicted during the pandemic. Therefore surveil-
lance of influenza-like illness (ILI) in outpatient children was launched by extending the 
surveillance scope of the already existing Paediatric Surveillance Network (PediSurv). This 
network consists of about 440 voluntary participating paediatricians and about 350 GPs in 
Brussels. It was set up as part of the epidemiological surveillance of communicable diseases 
in Europe and in the framework of polio eradication and measles elimination (4-5). Currently, 
PediSurv monitors the occurrence of acute flaccid paralysis, measles, mumps, Invasive 
Pneumococcal Disease (IPD), congenital rubella and haemolytic uremic syndrome. Although 
PediSurv is not an exhaustive surveillance system and calculation of incidence is not possi-
ble for all diseases, the stable participation rate allowed to observe trends and to detect 
clusters and outbreaks (6-7). 
This article describes how we introduced clinical and virological surveillance activities of in-
fluenza within this surveillance system and presents the results from week 39 until week 53 
of 2009. 
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Methods 
In June 2009, we asked all participating PediSurv paediatricians if they were willing to par-
ticipate in epidemiological and virological influenza surveillance. In September 2009, those 
wanting to participate received the questionnaires on the epidemiological surveillance. Fol-
lowing parameters were collected daily by the paediatricians and sent to the Scientific 
Institute of Public Health (WIV-ISP) on a weekly basis: the number of ILI and the number of 
people hospitalised for ILI by age group (<1 and 1-5), the overall number of consultations in 
0-5-year olds and the type of practice (private, hospital, emergency wards). Already hospital-
ised patients were excluded since these patients could also be monitored for SARI (8). The 
criteria for ILI were: sudden onset of fever with at least one respiratory symptom (cough, 
rhinitis, sore throat,…). This case definition was based on available literature and accepted 
by the PediSurv committee (9-10). 
The initial request in June 2009 for virological surveillance was to collect swabs 1 to 2 times 
per week in children presenting with ILI. However due to limited resources we had to restrict 
the number of samples to a maximum of 150 between week 39 (end of September) and 53 of 
2009. Therefore we selected 50 paediatricians based on geographical criteria. To avoid bias 
towards the more severe ILI cases, we asked to sample the first patient presenting with ILI 
symptoms after the 15th of each month. Two nasal and two throat swabs were to be collected 
from each child. A standardised questionnaire contained items on clinical presentation, hos-
pitalisation, antiviral treatment, risk factors and vaccination against influenza and IPD. 
Samples were analysed at the National Influenza Centre of the WIV-ISP and at the Univer-
sity Hospital Gasthuisberg in Leuven. A specimen was defined as influenza-positive if 
polymerase-chain-reaction (PCR) assays were positive for influenza A or B. A specimen was 
defined as A(H1N1)2009-positive if the results of the PCR A and A(H1N1)2009 were both 
positive (11). 
Data of week 52 and week 53 were analysed together. Data management and statistical 
analysis were done at the WIV-ISP, using Stata (version 10) and SAS (version 9.1)  
Results 
After the initial request in June 2009, 136 of the 440 paediatricians of PediSurv (31%) were 
willing to participate in the epidemiological surveillance. By October 2009, between 52 and 
65 paediatricians had effectively returned the weekly epidemiological questionnaire (average 
response of the network of 13%). 
From week 40 an increase of consultations attributed to ILI could be observed, following the 
same trend for the age groups <1 and 1-5 years (Figure 1). 
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Figure 1. Percentage of consultations attributed to influenza-like illness (ILI) in children 0-5 years old  
in paediatric practice (week 2009-39 to 2009-52/53) 
A maximum of 36% of consultations for ILI was reached in week 44 for the 0-5 years old and 
a smaller peak could be observed in week 49 with 21% of consultations for ILI. In the course 
of the epidemic, the overall weekly hospitalisation rate for ILI patients varied between 5 and 
10% (Table 1). The highest weekly hospitalisation rate was found in children <1 year old 
(17% in week 48).  
Table 1. Hospitalisation in children with influenza-like illness (ILI) reported by paediatricians  
(week 2009-39 to 2009-52/53) 
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In June 2009, 118 paediatricians were willing to participate in the virological surveillance. Af-
ter the selection of 50 paediatricians, an additional 19 paediatricians were addressed to 
increase the number of collected samples. By week 2009-53 we received samples from 88 
children of whom 24 (27%) had laboratory confirmed Influenza A(H1N1)2009. None of the 
samples were positive for other influenza types or subtypes. 
All children who were sampled had fever and 98% had at least one respiratory symptom 
(thus matching the case definition of ILI). Clinical presentation was similar for children with 
and without laboratory confirmed influenza, although headache was more present in labora-
tory confirmed cases (Figure 2). Most children had fever and cough or fever and rhinorrhoea 
(89%). Of all tested children, 6 required hospitalisation, of whom 5 were influenza-positive. 
Three of the children who were hospitalised and influenza-positive had a chronic respiratory 
condition. Two tested children were vaccinated against seasonal influenza vaccine (one in-
fluenza-positive); no-one was vaccinated with the pandemic vaccine. 
Figure 2. Proportion of patients according to clinical symptoms and laboratory results for influenza  
(n=88, week 2009-39 to 2009-52/53) 
Discussion 
The PediSurv network proved to be a flexible system which allowed rapid activation of a 
group of paediatricians. Introduction of the influenza surveillance confirmed the epidemic 
trend in children observed by the SGPs. Increase, peak and decrease in number of consulta-
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years old seen in general practice (3). The second smaller peak in ILI consultations coincides 
with a peak in RSV (Respiratory Syncytial Virus) circulation (12). 
This network allowed collecting a number of samples in the paediatric outpatient population. 
Our analysis confirmed the aspecificity of ILI criteria for influenza diagnosis: clinical presenta-
tion of A(H1N1)2009 infection is largely indistinguishable from that of other viral infections, 
but should still be used as a guide for who needs testing (13-14).  
The hospitalisation rate was the highest among children <1 year, which does not necessary 
reflect the severity of the disease, but can be due to short observational hospital admissions 
(15). Up to now, the majority of the cases of A(H1N1)2009 infection in children were mild and 
a recent serological study in England estimated that one child in three was infected, ten 
times more than estimated from clinical surveillance (16-17). 
Limitations of our surveillance are the low response and the inability to calculate incidences 
and thereby precluding the extrapolation of our results to the paediatric population. The will-
ingness to participate was 31% at the start, but actual participation was probably lowered by 
the considerable workload brought about by the questionnaire and the reduction in the num-
ber of samples we had to make for the virological part of the surveillance.  
We have demonstrated the potential for using PediSurv for emergency surveillance. This 
surveillance system has the advantage of being well-established and enabled access to epi-
demiological, clinical and virological data. The clinical surveillance of influenza however 
could not provide additional information during the course of the epidemic that was not al-
ready available from other surveillance systems. In the future a surveillance of only the 
severe hospitalised cases of influenza could be considered, as was conducted in the paedi-
atric surveillance network in Australia (18). Virological surveillance provided additional 
information on the clinical presentation of A(H1N1)2009 infection in young children, but re-
sources are needed to collect samples on a more regular basis during an epidemic. 
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